Ishibashi T, Yokoyama K, Shindo J, Hamazaki Y, Endo Y, Sato T, Takahashi S, Kawarabayasi Y, Shiomi M, Yamamoto T
First Department of Internal Medicine, Fukushima Medical College, Japan.
Arterioscler Thromb. 1994 Oct;14(10):1534-41. doi: 10.1161/01.atv.14.10.1534.
The mechanism by which granulocyte-macrophage colony-stimulating factor (GM-CSF) lowers plasma cholesterol levels is not well understood. We tested recombinant human GM-CSF (rhGM-CSF) on plasma cholesterol and triglycerides in rabbits and attempted to determine the mechanisms of the cholesterol-lowering effect. rhGM-CSF (20 micrograms.kg-1.d-1) was administered to normal and cholesterol-fed rabbits for 2 weeks and to Watanabe heritable hyperlipidemic (WHHL) rabbits for 1 week. The administration of rhGM-CSF markedly lowered cholesterol and triglycerides, an effect that persisted in normal and cholesterol-fed rabbits even after termination of treatment. The cholesterol-lowering effect of rhGM-CSF was also observed in WHHL rabbits. rhGM-CSF was capable of stimulating granulocyte-macrophage colony formation in vitro in rabbits with an effect comparable to that in humans. Northern blot analysis with rabbit very-low-density-lipoprotein (VLDL) receptor cDNA revealed that rhGM-CSF increased the levels of VLDL receptor mRNA in muscle of rabbits after only 1.5 hours of treatment compared with control (2.6-fold), with the 1.5-fold increase following a 5-day administration. No changes in the levels of LDL receptor mRNA in liver, spleen, and bone marrow were observed in the treated rabbits. These findings suggest that the cholesterol-lowering effect of rhGM-CSF may be mediated by enhancement of macrophage functions in lipid metabolism and the increase in mRNA for VLDL receptor in rabbits.
粒细胞-巨噬细胞集落刺激因子(GM-CSF)降低血浆胆固醇水平的机制尚未完全明确。我们在兔身上测试了重组人GM-CSF(rhGM-CSF)对血浆胆固醇和甘油三酯的影响,并试图确定其降胆固醇作用的机制。将rhGM-CSF(20微克·千克⁻¹·天⁻¹)给予正常兔和喂食胆固醇的兔,持续2周,给予渡边遗传性高脂血症(WHHL)兔,持续1周。rhGM-CSF的给药显著降低了胆固醇和甘油三酯,即使在治疗终止后,这种作用在正常兔和喂食胆固醇的兔中仍然持续。在WHHL兔中也观察到了rhGM-CSF的降胆固醇作用。rhGM-CSF能够在体外刺激兔的粒细胞-巨噬细胞集落形成,其效果与在人类中的效果相当。用兔极低密度脂蛋白(VLDL)受体cDNA进行的Northern印迹分析显示,与对照组相比,rhGM-CSF在仅治疗1.5小时后就使兔肌肉中VLDL受体mRNA水平增加(2.6倍),在给药5天后增加1.5倍。在接受治疗的兔中,未观察到肝脏、脾脏和骨髓中LDL受体mRNA水平的变化。这些发现表明,rhGM-CSF的降胆固醇作用可能是通过增强巨噬细胞在脂质代谢中的功能以及兔中VLDL受体mRNA的增加来介导的。